Early day motion tabled by primary sponsor Nick Harvey (Liberal Democrat), on Thursday, 10 October 2013, in the House of Commons. It is signed by 25 members in total.

---

ADVERSE PSYCHIATRIC EFFECTS OF ROACCUTANE

That this House notes with great concern that the Roaccutane form of isotretinoin has been implicated in reports of 878 psychiatric disorders, including 44 suspected suicides, since its registration in 1983; further notes that Roche, the drug's manufacturers, maintain that there is no causal link between Roaccutane and suicidal tendencies; further notes that its variant in the US, Accutane, has proved controversial and was withdrawn from the US market as a commercial decision following mounting litigation; further notes that clinical studies using the drug on rats and mice have discovered evidence of disruption to serotonin levels, causing depression, but that similar studies have not been conducted on humans; and urges, in light of the increasing number of tragic suicides of recent years, the withdrawal of Roaccutane from the UK market pending further and full investigations into adverse reactions to the drug, to prevent further unnecessary deaths.

---

Secondary information

Type

Early day motion

Reference

556 

Session

2013-14

Other sponsors

Paul Flynn

Mark Durkan

Andrew Rosindell

Gordon Henderson

Richard Drax

Subjects

Health services Mental health Medicine

Link

View this Early day motion on www.parliament.uk